WHO and OneSight EssilorLuxottica partner to expand vision care in Karnataka

WHO’s global SPECS 2030 target to increase effective refractive error coverage by 40% by 2030

VectorBuilder Redefines Plasmid Standards with miniVec

Conventional plasmids as a pharmaceutical material are not only suboptimal in safety and function, but exceedingly costly to produce, prohibitively

Lupin to build $250 million manufacturing facility in Florida

Furthering?U.S.-based?pharmaceutical?capacity?to?produce?critical respiratory medicines?

IMCD unveils future of beauty at In-Cosmetics Latin America 2025

IMCD engaged with manufacturers, formulators, and brand leaders, offering valuable insights into evolving consumer trends

FDA supports new ANDA prioritization pilot to support US generic drugs

Nanavati Max, Uzbekistan’s NVRH forge alliance to advance healthcare and training

Wockhardt submits NDA to USFDA for Zidebactam-Cefepime injection

The NDA submission follows the successful completion of a pivotal Phase III global clinical trial

BMS’s anti-MTBR-Tau granted fast track designation by FDA for Alzheimer’s disease

Anti-microtubule binding region-tau antibody being investigated as a potential disease-modifying therapy to slow or delay progression of disease

Amgen’s Phase III data supports FDA label expansion of Repatha

Repatha is now the first and only PCSK9 inhibitor to demonstrate significant reduction of cardiovascular events as both primary and secondary prevention

Winrevair cuts risk of PAH progression by 76% in phase 3 Hyperion trial

Hyperion results presented at ERS 2025 and simultaneously published in the New England Journal of Medicine